Planned trial compares injectable antipsychotics to usual care for psychosis with stimulant use

Status: COMPLETED | Phase: PHASE2/PHASE3 Condition(s): Stimulant Use With Stimulant-Induced Psychotic Disorder (Diagnosis), Schizophrenia and Related Disorders, Stimulant Dependence, Stimulant Abuse, Pharmacotherapy Intervention(s): Aripiprazole (DRUG), Paliperidone (DRUG), Treatment as Usual (OTHER) In Hong Kong, less than 5% of stimulants abusers were reported to misuse these substances via injection. Also, it is well known that patients with co-morbid substance abuse/dependence and psychosis or schizophrenia-related disorders are prone to earlier treatment discontinuation and high oral medication non-adherence, resulting in poorer overall outcomes. With the recent availabilities of the 4-weekly long-acting injectable form of aripiprazole, and the 4-weekly and the 3-monthly long-acting injectable form of paliperidone palmitate, on the background of the surging phenomenon of stimulant misuses in Hong Kong, it is a timely opportunity to conduct an early pharmacotherapy intervention study to offer an evidence-based strategy aiming to stop individuals with substance use disorders with psychosis to develop into a more chronic disabling dependence or co-morbid state. Primary Outcome(s): Efficacy on psychosis management as measured by the Clinical Global Impression Enrollment: 165 (ACTUAL) Lead Sponsor: The University of Hong Kong Start: 2019-06-01 | Primary Completion: 2024-05-31